Zacks Investment Research cut shares of Antares Pharma Inc. (NASDAQ:ATRS) from a buy rating to a hold rating in a research note published on Tuesday.
According to Zacks, “Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients. The Company currently distributes its needle-free injector systems for the delivery of insulin and growth hormone in over 20 countries and an estradiol transdermal patch for hormone replacement therapy. “
Separately, Piper Jaffray Cos. restated an overweight rating and set a $2.00 target price (down from $3.00) on shares of Antares Pharma in a report on Saturday, August 13th.
Shares of Antares Pharma (NASDAQ:ATRS) opened at 1.76 on Tuesday. The firm has a 50-day moving average of $1.51 and a 200 day moving average of $1.12. The company’s market cap is $272.90 million. Antares Pharma has a 52 week low of $0.67 and a 52 week high of $1.85.
Antares Pharma (NASDAQ:ATRS) last posted its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.04). Antares Pharma had a negative net margin of 54.98% and a negative return on equity of 41.06%. The firm earned $12.20 million during the quarter, compared to the consensus estimate of $11 million. During the same period last year, the firm posted ($0.01) EPS. Equities analysts expect that Antares Pharma will post ($0.15) EPS for the current fiscal year.
Several large investors have recently modified their holdings of ATRS. Janus Capital Management LLC purchased a new stake in shares of Antares Pharma during the second quarter worth approximately $102,000. Oppenheimer & Co. Inc. increased its stake in shares of Antares Pharma by 19.1% in the second quarter. Oppenheimer & Co. Inc. now owns 112,300 shares of the specialty pharmaceutical company’s stock worth $118,000 after buying an additional 18,000 shares during the period. Jane Street Group LLC purchased a new stake in shares of Antares Pharma during the second quarter worth approximately $133,000. LMR Partners LLP purchased a new stake in shares of Antares Pharma during the second quarter worth approximately $297,000. Finally, Royce & Associates LP increased its stake in shares of Antares Pharma by 318.3% in the first quarter. Royce & Associates LP now owns 406,900 shares of the specialty pharmaceutical company’s stock worth $354,000 after buying an additional 309,616 shares during the period. Institutional investors and hedge funds own 36.34% of the company’s stock.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.